Drug Combination Details
| General Information of the Combination (ID: C56032) | |||||
|---|---|---|---|---|---|
| Name | Celastrol NP Info | + | Tanespimycin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Brain cancer
[ICD-11: 2A00]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Biological
Regulation |
Induction | Proteotoxic stress | ||||
| In-vitro Model | U-251MG | CVCL_0021 | Astrocytoma | Homo sapiens | ||
| U-343MG | CVCL_S471 | Glioblastoma | Homo sapiens | |||
| Experimental
Result(s) |
celastrol targets proteostasis by disrupting sulfyhydryl homeostasis, independently of ROS, in human glioblastoma cells. Targeting proteotoxic stress responses by inhibiting HSP90 with 17-N-Allylamino-17-demethoxygeldanamycin sensitizes human glioblastoma to celastrol treatment, thereby serving as a novel synergism to overcome drug resistance. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Celastrol targets proteostasis and acts synergistically with a heat-shock protein 90 inhibitor to kill human glioblastoma cells. Cell Death Dis. 2014 May 8;5(5):e1216. | |||
